Академический Документы
Профессиональный Документы
Культура Документы
MATEPH H PE6EHKA
nepuonuqecKuii nayqno-npaKTnqecKuii:
Me)J;HQHHCKHH ~ypnaJI
flE,l{l1ATP11J/
3manbl Hay'lHblX UCCJle006QHUU
no npo6neMe 6poHxone20tJHou namonocuu
compyoHUK06 H~OMuP K&ip2bl3CKou Pecny6nuKu
JHa'leHUe yp06Hfl 3pumpono3mUHa 6 OUa2HOCmUKe U
MOHUmOpUp06QHUU aHeMUU y Oemeu
On&im npUMeHeHUR «AcKopW1a» 6 KOMfl!leKCHOM netJeHuu
6o!le3Heu op2aH06 OblXQHWI. y oemeu
Oco6eHHocmu 3muonocutJecKou cmpyKmyp&l ocmpo20 o6cmpyKmU6H020
6pOHXUma y Oemeu paHHezo 603pacma
CmpyKmypa u <jJyHKl/Ufl 3pumpol/umapHblX MeM6paH npu :>1eene3ooe<fJullumHou
aHeMUU cpeOHeU cmeneHU mR:>ICecmu y oemeu
WKO!lbH020 603pacma 6 2opHblX ycno6URX
l1mo2u u nepcneKmU6bl pa36UmUR UHUl/UamU6bl 006po:>1eenamen&Ho20
omHoweHUfl K Mamepu u pe6eHK)l (11EPOMuP) 6 K&ip2&l3cmaHe
Co6peMeHHble 603MO:>ICHocmu 6uono2utJecKou mepanuu ocmpo20 6poHxuma
XpoHutJecKaR Kpanu6HUl/a Ha 102e K&ip2&13cmaHa: npo6!leMbl
u nymu peweHUR
CotJemaHHble 3a6one6aHUR npu xpoHutJecKou 2acmpooyooeHCIJlbHou
namO!l02UU y WKOJlbHUK06
AKYlllEPCTBO 11 I'l1HEKOJIOI'l1J/
OnmUMU3al/Ufl 6eOeHUfl 6epeMeHHocmu u pooo6 y :>1eeHU,UH
c JleUOMUOMOU MamKU (o63op numepamypbl)
Ol/eHKa 3</J</JeKmU6Hocmu 6a2Z1HCIJlbH020 pacm6opa u6ynpo</JeHa
U3o6ymaHOllaMMOHUfl npu Jle'leHUU 6a2UHUm06
/IETCKAJ/ XlfPYPI'l1J/
/VzuHU'leCKUe oco6eHHOCmu MHO:>ICeCm6eHH020
U CO'lemaHH020 3XUHOKOKK03a ne'leHU y oemeu
J13ytJeHue 3nUOeMUO!l02UU 3y6otJen10cmHblX aHOMCIJlUU
,V Oemeii II nnOpOC/11K06
5. OecRHHUKoea T.B., I'ypuee T.J( 20022. MuoMa MamKu: CoepeMeHHble npo6fleMbl 3muoJ102uu,
namo2eHe3a, iJuawocmuKu u !letteHUR: PyKoeoocmeo O!lR epatteu. M: 2002. - 328 c.
6. H6pa2UMoea /(.M, J{o6poKomoea 10.3 . 3.MOO!lU3atJUR Mamo'lHblX apmepuu e aKyutepcmee u
2uHernJ102uu II PoccuiicKULt MeOUtJUHCJ..:uu JK:YPHa!l. - 2014. -Ml. - C. 42-47.
7. HU{-eHKO A.H. , EomeuH MA. , JlaH'lllHCk'UU B.H. PenpooyKmueHble npo6.T1eMb1 onepupoeaHHOu
MamKu. - M: MwUlout, 2007. - C. 16-22.
8. KapUMoe 3./(. c coaem. K01-1cepeamueHGR .M uo,,~3KmOMUR e npo6J1eMe eoccmaHoefleHUR
<fJepmU!lbHocmu y MO!lOOblX JK:eHUf-UH II JKypHa!l aKyutepcmea u JK:eHCKUX 6o!le3Heu. - 2011. - M4. - C.
147-150.
9. KpacHono!lbCKUU B.H., CuttuHaea JI.I'. , KaJ1y2uHa <t>.C. PenpooyKmueHble npo6J1eMb1
onepupoeaHHOu MamKu. - M: MwUlout, 2005. - 162 c.
JO. Ky!laKoe B.H. , lllMaKoe I'.C. MuoM3KmOMUR u 6epeMeHHOCmb. - M : MEJ(npecc-uH<jJopM,
2001. - 342 c.
11. JluHiJe B.A., J{o6poeo!lbCKuu HC. , c coaem. MuoMa MamKu u MUOM3KmoMUR. - M: MHA,
2010. -C. 122-126.
12. PbzMauwecKuu A.H. c coaem. Po!lb !letloMUOMbl MamKu e eo3HUKHOBeHuu 6ec11.!loiJuR II
BecmHUK poccuucK020 yHueepcumema iJpyJ1C6b1 Hapoooe. - 2012. - M3. - C. 15-17.
13. Cuoopoea H.C. MuoMa MamKu. -M: MHA , 2003. -C. 27-32.
14. CaeutJKUU I'.A ., Caeu4Kuu A.I'. MuoMa MamKu. «3JlCElf-CilE». - 2003. - C. 152-159.
15. TuxoMupoe A.JI., Jly6HUH J(M MuoMa Mam Ku. - M: MlfA , 2006. - C. 106-115.
16. Cobellis L., Pecori E. , Cobellis G. Hemostatik technigue for myomectory during cesarean
section II Int. J Gynaecol. Obstet. - 2002. - Vol. 79. - P. 261.
17. Cooper NP., Okolo S. Fibroids in pregnancy - common but poorly understood. Obstet.
Gynecol. Surv. - 2005. - Vol. 60. - P. 132.
18. Donnez J , Jadoul P. What are the implications of myomas on fertility? A need for a debate?
Human Reprod. 2002. - 17: 6: P. 1424-1430.
19. Ehigiegba A.E., Ande A.B. , Ojobo SI. Myomectomy during cesarean section. Int. J Gynaecol.
Obstet. - 2001. - Vol. 75. -P. 21.
20. Hanafi MMD. Predictors ofleiomyoma recurrence after myomectomy. Obstet. Gynec. 2005.
- 105: P. 877-881.
21. Jabiry-Zieniewicz Z,, Gajewska M The pregnancy and delivery course with pregnant women
with uterine myomas. Ginekol. Pol. - 2002. - Vol. 7. - P. 46-50.
22. Lethaby A., Voolenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin. Evid. 2004;
2406. - P. 26.
23. Somigliana E. , Vercellini P., Daguatil R. et al. Fibroids and female reproduction: a critical
analysis of the evidence. Human Reprod. Update 2007. - 13: 5: P. 465-476.
O~EHKA3~~EKTHBHOCTHBArHHA~LHOrOPACTBOPA
HI>YIIPO~EHA H30I>YTAHOMMMOHIDI IlPH ~EqEHHH
BArHHHTOB
Ca.Mu2yJU1u11a A.3., MaKcymoBa 3.M., Capb16aeBa K.A.
HatJUOHa!lbHblU 4eHmp oxpaHbl MamepUHCmea u oemcmea,
EuwKeK, Kb1p2b13CKGR Pecny6fluKa.
Resume: the randomized controlled clinical trial for evaluation of efficacy of vaginal solution of
ibuprofen isobutanolammonium in vaginitis was conducted in National Center for Care of Maternity and
Children Health. Advantages in clinical features in patients treated with experimental regimen have been
shown after 2nd day of therapy, as well as reducing of complaints of vaginal pain (5.1-fold, p< 0. 001),
itch (by 80%, p<0.001), burning (by 40%, p<0.001) and vaginal discharges (by 40%, p<O.OOl)and also
was reported improvement of vaginitis clinical pattern. Trial results demonstrated effectiveness of
ibuprofen isobutanolammonium vaginal solution for treatment of vaginitis and confirmed its significance
as valuable and perspective agent for early and reliable control of vaginal symptoms.
Key words: vaginitis, symptom severity, ibuprofen isobutanolammonium vaginal solution.
52
-
Ivrn:HHKa sarHHHTOB xapaKTepH3yeTcH o6HJII>HhIMH si,meneHHHMH H3 rrorroBI>IX rryTeH:,
pa3.npa)l(eHHeM, 3YLJ:OM H )l()l(eHHeM [6-8, 11, 12]. ,[(JUI JieqeHH.H BarHHHTOB Hap.Hey co
crreu:mlmqecKHMH aHTHMHKpo6HhIMH cpe.ncTBaMH peKOMeHeyeTCH rrpHMeHeHHe MeCTHhlX
rrpOTHBOBOCIIaJIHTeJihHhIX cpe.ZJ;CTB [13, 14]. 0.ZJ;HHM H3 peKoMeHJzyeMhIX KJiaCCOB cpe.ZJ;CTB
HBJIHIOTCH BarHHaJihHhie opomeHH.H paCTBOpaMH HecTepOH.ZJ;HhIX rrpOTHBOBOCIIaJIHTeJihHhIX
areHTOB [14-17]. Bee BhIIIIeCKa3aHHOe IIOCJIY)l(HJIO OCHOBaHHeM .ZJ;JIH IIJiaHHpOBaHHH H
rrpose.neHH.H .naHHOro HCCJie.ZJ;OBaHHH.
l.(ellb UCC/leOOBllllUR - ou;eHHTh 3<l><l>eKTHBHOCTh BarHHaJihHOro pacTBopa H6yrrpo<l>eHa
H3o6yTaHOJiaMMOHRH rrpH TepaIIHH Hecrreu:H<l>HqecKHX BarHHHTOB.
Mamepullll u .MemoObl ucCJ1e00Ba11ua. AHaJIH3 rrpose.nettHoro c BarHHaJihHhIM pacTBopoM
H6yrrpo<l>etta mo6yrnHOJiaMMOHHH KJIHHHqecKoro HCCJie.ZJ;OBaHRH ou;eHHBaJICH l{a cyfo.eKTHBHhIX
ou;eHKax CHMIITOMOB rrau;HeHTKH rrpH IIOMOIUH Bep6aJihHhIX paHroB:LIX IIIKaJI H Blf3YaJihHOH
attanorosoH: IIIKaJih! (BAlll) [18-23]. KpoMe rnro 6i,ma rrpose.neHa 061.eKTHBHaH ou;ettKa
COCTOHHH.H rrau;HeHTKH ( CTerreHh Bl>Ipa)l(eHHOCTH Ha6mo.naeMhIX npH3HaKOB 3a60JieBaHHH)
rreqaIUHM BpaqoM rrpH IIOMOIUH paHrOBOH IIIKaJihl ou;eHKH (lllOIT). I1H.ZJ;HKaTOpaMH ou;eHKH
HBHJIHCh: yMeHbIIIeHHe 6orrH, .ZJ;HCKOM<i>oprn, )l()l(eHRH H pa3,n:pa)l(emrn.
Hccrre.nosaHHe rrposo.nHrroci, Ha 6a3e oT.neneHH.H «I>paK H CeM1>H» HU:OMH,[( 3a rrepHo.n
MaH:-ceHrn6pi, 2015 ro.na. B Hccrre.nosaHHH rrpHHHJIH .no6poBOJII>Hoe yqacTHe 60 rrau;HeHTOK B
B03pacTe 18-55 rreT, o6paTHBIIIHXC.sI B U:eHTp ITO IIOBOLJ:Y BarHHJITa c rro.nrnep)l(LJ:eHHhIM
.ZJ;HarH030M. B Kaqecrne rrperrapaTa H6yrrpo<l>etta mo6yrnHOJiaMMOHH.H 6i,m HCIIOJih30BaH
3aperHcTpHpoBaHHhIH B KP pacTBop sarHHaJihHhIH «fHHeHopM».
B KaqecTBe crreu;H<l>HqecKoro rrpoTHBOMHKpo6Horo cpe.ncrna BI>16paHhI
3aperHcTpHposaHHI>Ie B KP sarHHaJII>Hh!e cseqH «0ByMHKC» , co.nep)l(amHe aHTHMHKpo6Hh!e
cpe.ZJ;CTBa IIIHpOKOro crreKTpa .neH:CTBHH (MHKOHa30JI, MeTpOHH.ZJ;a30JI, HeOMHU:HH, IIOJIHMHKCHH) H
06na.na10mHe paH03a)l(HBJIHIOIUHM CBOHCTBOM.
DOJihHble 6I>mH pa3.n;eJieHhI Ha 2 rpyrrrrhI - KOHTpOJihH)'IO, IIOJIY'-IaBIIIYIO CTaH.n;apTHOe
JieqeHHe crreu:H<l>HqecKHM rrpoTHBOMHKpo6HhIM cpe.n;CTBOM ( CBeqH BarHHaJihHhie) H
3KcrrepHMeHTaJII>HyIO, rronyqasmyio a.no6aBOK K YKa3aHHOMY crnH.napTHOMY rreqeHHIO pacrnop
BarHHaJihHhIH H6yrrpo<l>eHa mo6yrnHOJiaMMOHHH ( opomeHIDI BarnHaJihHble ).
,[(IIH o6ecrreqeHH.H cnyqaifHOCTH BhI6opa rrau;HeHTOK 6i,m rrpHMeHeH MeTO.n; rrpoCTOH
tPHKCHpOBaHHOH paH,ll;OMH3aU:HH, rrpH IIOMOIUH HOMepKOB B KOHBepTax: HeqeTHhIB HOMep -
3KCIIepHMeHTaJihHhIH pe)l(HM, qeTHhIH HOMep - KOHTpOJihHhIH.
Ou;eHKa 3<l><l>eKTHBHOCTH rreqeHHH rrposo.n;Hrraci, Ha 3-B: .n;etth neqeHHH H Ha 2-H: .neHI> rrocne
rreqeHHH.
,[(IIH orrpe.n;eJieHH.H 061:.eMa BhI6opKH rrau;HeHTOK B Ka)l(LJ:OH rpyrrrre HCfIOJih30BaJiaCh
peKOMeHeyeMaH CTaTHCTHqecKM <l>opMyJia rro.n;cqern pa3Mepa paHL{OMH3HpoBaHHOH BhI6opKH
.lJ:JIH Ka)l(LJ:OH H3 rpyrrrr B rrapanJieJihHhIX cpaBHHTeJihHhIX HCCJie.n;oBaHH.HX [24]:
z{j2(.zl - o/2 -+ .Zp)2
n per group = A2
ITpH 3TOM BbUIBJieHo, qTo 6oJihIIIe scero rraa;HeHTKH )l(aJIOBaJIHCb Ha sarHHaJibHbIM 3Y.LJ:
(60%), BarnHaJibHOe )l()l(eHHe (79%) H BarnHaJibHble Bbl,[(eJieHIDI (100%). OcTaJibHbie CHMITTOMbl
oTMeqaJIHCb He 6oJiee, qeM y 1/3 )l(eHia;HH: 3TO - BarHHaJibHllil 60Jib (23%), BJIIDIHHe BarHHHTa
Ha ITOJIOBOM aKT (33%), BJIIDIHHe Ha crropTHBttyIO aKTHBHOCTb (30%) H BJIH51HHe Ha COll;HaJibttyIO
aKTHBHOCTb (28%). lfcxo,[(Hbie xapaKTepHCTHKH o6'beKTHBHOM oa;eHKH rrpH3HaKOB BarHHHTa
Jieqaia;HM BpaqoM y rraa;HeHTOK rrpencTaBJieHbl B Ta6JI. 2, KaK BH,[(HO H3 Ta6JIHll;bl o6e rpyrrrrhI
COITOCTaBHMbl H He HMeIOT ,[(OCTOBepHbIX pa3JIHqH:M, p>0,05.
B xone o6cJienosaHHH yCTaHOBJieHo, qTo 6oJihIIIe scero cpen11: rraa;HeHTOK BhUIBAAJIHCb
rroKpacHeHHe CJIH3HCTOM BJiararr11:ma (98%) H rnrrepeMIDI KO)l(H BYJihBapHoH: o6JiaCTH (67%). B
MeHbIIIeH: CTerreHH Ha6JIIO,[(aJIHCb JieMKOKCaHTOpe51 ( 41 % ) H B 3HaqH:TeJibHO MeHbIIIeH: Mepe -
ne3ITHTeJIH3aa;H51 CJIH3HCTOM BJiaraJIHia;a (2%).
,ZJ;arree HaMH rrposeneHa oa;eHKa pe3yJihTaToB JieqeHHH Ha 3-H: neHb c MOMeHTa Haqarra
TeparrHH (rrepBbie pe3yJibTaTbl) H Ha 2-H: neHb IlOCJie OKOHqaHIDI eypca JieqeHH51
( OKOHqaTeJibHbie pe3yJibTaTbl).
B pe3yJihTaTe rrposeneHHoro HccJienosaHIDI ycrnHOBJieHo, qTo (rn6JI. 3) rrpH
cy6neKTHBHOM oa;eHKe (no IIIKaJie BAlll) rraa;HeHTaMH CHMITTOMOB BarHHHTa Ha 3-H: neHb
54
-
rreqeHHH OTMeqarroch CTaTHCTttqeCKH 3HaqJIMOe nocTOBepHoe y.rryqIIIeHHe CHMilTOMaTHKH no
cpaBHemno c HaqarroM rreqeHIDI B o6eHX rpyrrrrax no BceM rrapaMeTpaM, KpoMe BarHHaJibHOii
6orrH B rpyrrrre KOHTpOJIH, p=0,19. Oco6o 3Ha'IHMoe y.rry~eHHe Ha6monarroch B o6ettx rpyrrrrax
B yMeHbIIIeHHH )Ka.JI06 Ha BbmerreHIDI H3 IIOJIOBbIX rryTeH:, p<0,01.
• KOHTPOflb, yny4weHHO
• P<0.001
·. 3KCnEPlllMEHT. Y"Y"WOH"'O
Puc. 1. Cy6beKrnueHM OlfeHKa Ha 3-u iJeHb Jle1.JeHuR (2-u eU3um) e cpaeHeHuu c ucxoOHblMU
noKa3arneJlJLMU (1-u eu3urn).
lfa Ta6rr. 4 HarmnHo BHnHo, qro B xone 3KcrrepHMeHTa 6hrna noKa3aHa 6orree BhICOKaH
'.)<P<PeKTHBHOCTb rreqeHHH BarHHHTa rrpH no6aBJieHHH K CTaHnapTHOMY rrpoTHBOMHKpo6HOMY
pe)KHMy pacrnopa BarHHaJihHOro tt6yrrpo<PeHa mo6yTHJiaMMOHHH. CornacHo rro.rryqeHHhIM
naHHbIM, BarHHaJibHbIB paCTBOp, rrpHMeHHeMbIB B rpyrrrre 3KCrrepHMeHTa CTaTHCTHqecKH H
KJIHHHqecKH nocTOBepHO ycKOpHeT Hcqe3HOBeHHe TaKHx CHMilTOMOB, KaK BarHHa.JlbHbIH 3yn B
9,6 pa3 6bICTpee KOHTpOJibHOH rpyrrllbI, BarHHaJibHaH 60Jib rrepecTaeT 6ecrroKOHTb B 7,8 pa3
qaine, BarHHaJibHOe )K:>KeHHe Hcqe3aeT B 5,6 pa3 6hICTpee, B 4,9 pa3 6bICTpee BarHHHT rrepecTaeT
MeIIIaTb crropTHBHOH aKTHBHOCTH :>KeHrrnrn. I1pH 3TOM, IlOKa3aTeJIH CHMilTOMaTHKH B rpyrrrre
55
3KCnepI1MeHTa CHmI<aJIIICh B pa3hI (B 3-10 pa.3), a B rpynne KOHTpOml - He 6onee, qeM Ha 50%
no nOKa.3aTemIM BarIIHaJihHOH 60.TIII II BarIIHaJihHOro 3y.na II B 3,4 pa.3a - no nOKa.3aTemo
BJIIDIHIDI Ha CO:UilaJihHYIO aKTIIBHOCTh.
TaKHM o6pa.30M, HayqHo .JJ.OKa.3aHa poJih pacrnopa aarnHaJihHoro I16ynpo<iieHa
mo6yTI1JiaMMOHm1 B )J.OCTil)l(eHIIII BhICOKOH 3<li<lieKTIIBHOCTII KJIIIHHqeCKOH TepanIIII aarIIHIITa y
nauI1eHTOK 3KCnepI1MeHTaJihHOH rpynnhI B cpaBHeHIIII c KOHTpOJihHOH y)l(e K TpeTbeMy )J.HIO
JieqeHIIH, npII 3TOM BarIIHaJihHhIB paCTBOp )J.OCTOBepHO nyqme 06ecneqI1aaeT Ha)J.e)l(HhIH
KOHTpOJih B OTHOIIIeHIIII 60.TihIIIIIHCTBa 6ecnoKOHIIJ;HX nauileHTKY CIIMnTOMOB, p<0,001.
TQ6JlUlfQ 5 - 06beKmueHaJI. OlfeHKQ no utKaJle l!JOII HQ 3-u oeHb JleIJeHuJI. (2-u euJum) e
CfJQBHeHuu c ucxoOHblMU noKmQmellJl.MU /1-u euJum).
[/QpaMempbz KoHmf)Ollb 3KcnepUMeHm
M±m YllYIJuteHue P* M±m YllY'luteHue P*
IloKpQcHeHue c!luJucmou 1,0±0,3 1,8 <0,01 0,8±0,5 2 <0,01
I'unepeMUJI. KO:JICU 0,5±0,6 1,1 <0,01 0,1±0,3 1,7 <0,01
JleuKoKCQHmopeJI. 0,4±0,5 1,2 <0,01 0,2±0,5 1,0 <0,01
J(e3numellU3QlfUJI. 0,1±0,3 0,1 0,35 0,0±0,0 0,1 <0,05
cRUJucmou
P* - cpaenenue c ucxooHblMU oaHHblMU (eu3um M2 c 6U3Umo.M Ml) .
'I •··'
6 ~ '
..
s \
2 ;
I\
Q ,,
• KOHTPOflb, ynyyweH11te
• 3KCnEPll1MEHT, ynyYWeHl!le
Puc 2. Cy6oeKmU6HQ}l, OlJeHKQ U3MeHeHU}l, CUMnmOM06 HQ 2-u oeHb nocJle Jlel.leHU>l,
(oKOHl.lQmeflbHble pe3yflbmambl) no cpQeHeHu10 c Hal.la'JlOM J1el.leHw1: cpQeHeHue Mexoy
2pynnaMu.
57
B pe3yJihTaTe rrpoBe.n;eHHOro HCCJie.n;oBaHHH ycrnHOBJieHO, qrn (rn6rr. 8) K KOHizy rreqeHHH
rrpH 061,eKTHBHOH ou;eHKe rrorryqeHHhIX pe3yJihTaTOB )J;OCTOBepHbIX pa3JIHqHH: B o6eHX
Hccrre.n;yeMhIX rpyrrrrax TaK>Ke He Ha6mo.n;arroch, p>0,05.
B xo.n;e 3KcrrepHMeHTa .D;OKa3aHo, qTO OTMeqaeTcH Bhipa)l(eHH~ J<l><l>eKTHBHOCTh BJIHHHHH
Ha cy6'heKTHBHhie IIOKa3aTeJIH rrpoHBJieHHH BarHHHTa H HeKOTOpoe BJIHHHHe Ha o6'heKTHBHbie
rrpH3HaKH 6orre3HH rrpH .n;o6aBJieHHH K CTaH.n;apTHOMY rreqeHHIO BarHHaJihHOro pacrnopa
H6yrrpo<l>eHa H3o6yTHJiaMMOHHH.
58
16. Lanza P. Efficacy and safety of a 7-day course of miconazole associated with
ibuprofenisobutanolammonium compared to therapy with miconazole alone in mycotic vaginitis [Text] I
Lanza P., Corea D., Mastrantonio P. II Gazzetta Medica ltaliana Archivio per le Scienze Mediche, 2000.
-April. 159(2). -p. 71-8.
17. Milani M Vaginal use of Ibuprofen isobutanolammonium (ginenorm) : efficacy, tolerability,
and pharmacokinetic data: a review of available data [Text] I Milani M, Iacobelli P. II ISRN Obstet
Gynecol, 2012. - Ch. 673,131. -p. 1-6.
18. Sullivan G.M Analyzing and Interpreting Data From. Likert-Type Scales [Text] I Sullivan
G.M , ArtinoA.R. II JGrad Med Educ, 2013. -Dec. 5 (4). -p. 541-542.
19. Stinson J.N. Systematic review of the psychometric properties, interpretability and feasibility
of self-report pain intensity measures for use in clinical trials in children and adolescents [Text] I Stinson
J., Kavanagh T., YamadaJ. eta/. II Pain, 2006. - Nov. 125(1-2). -p. 143-57.
20. Witt A. Monthly itraconazole versus classic homeopathy for the treatment of recurrent
vulvovaginal candidiasis: a randomised trial [Text] I Witt A. et al. II BJOG, 2009. - Oct; 116 (11). -
p.505.
21. Todd K.H. The minimum clinically important difference in physician-assigned visual analog
pain scores [Text] I Todd K.H., Funk J.P. II AcadEmerg Med, 1996. - Feb. 3(2). -p. 142-6.
22. Pickard A.S. Estimation of minimally important differences in EQ-5D utility and VAS scores
in cancer [Text] I Pickard A.S. et al. II Health Qua/ Life Outcomes, 2007. - Ch.5. - p. 70.
23. Bodian CA . The visual analog scale for pain: clinical significance in postoperative patients
[Text] I Bodian CA . et al. II Anesthesiology, 2001. -Dec. 95(6): 1356. - p.61.
24. Durham T.A . Sample size for continuous outcomes in superiority trials [Text] I Durham T.A .,
Turner J.R. II Introduction to Statistics in Pharmaceutical Clinical Trials. Pharmaceutical Press: London
(UK), 2008. -Ch.12. -pp.173-174.
25. Candiani G.B. Therapeutic effect and tolerability of the formula "SC 501" packets of 1 g in
inflammat01y processes of the vulvovaginal complex (controlled study vs. placebo) lstitutiClinici di
perfezionamento ''L. Mangiagalli" Obstetrics and Gynecology Clinic {:J!leKmpoHHbltl pecypc] I Candiani
G.B. II University of Milan. Prima Clinica, 1987.
59